skip to content

Who Uses CDD?

Organizations that benefit from CDD


  • ASINEX
  • BioSeek, Inc.
  • Broad Institute
  • Cedars-Sinai Medical Center
  • Columbia University
  • Cornell University
  • Drugs for Neglected Diseases initiative
  • Fred Hutchinson Cancer Research Center
  • Harvard University
  • Indiana University
  • Indiana University-Purdue University Indianapolis
  • Johns Hopkins University
  • Louisiana State University
  • LITMUS, LLC
  • Marine Biological Laboratory
  • Massachusetts Institute of Technology
  • Melior Discovery, Inc.
  • MOLISA GmbH
  • Myelin Repair Foundation
  • NIMH Psychoactive Drug Screening Program
  • Numerate, Inc.
  • Ohio State University
  • Public Library of Science
  • Purdue University
  • The Rockefeller University
  • San Francisco VA Medical Center
  • Scripps Research Institute
  • Seattle Biomedical Research Institute
  • Semafore Pharmaceuticals, Inc.
  • St. Jude Children's Research Hospital
  • Stanford University
  • STATegics, Inc.
  • TimTec, Inc.
  • Torrey Pines Institute for Molecular Studies
  • UCSF General Hospital
  • University of California, Berkeley
  • University of California, Los Angeles
  • University of California, San Francisco
  • University of California, Santa Cruz
  • University of Cape Town
  • University of Mississippi
  • University of North Carolina
  • University of Pennsylvania
  • University of Pittsburgh
  • University of Sydney
  • University of Texas
  • University of Washington

Testimonials

"One of the biggest barriers for academic drug discovery is the poor access to chemical data represented in an intelligent format. CDD presents data and associated tools that capture the relationship between chemical structure and biological activity. Structure-Activity Relationship (SAR) data substantially improve the distributed drug discovery process."

— Christopher Lipinski, PhD, Pfizer, Retired

"Five years ago our lab tested 20 compounds a year with no way to handle 200. Today, with CDD's software, we can fully process 3,000 new compounds per year and advance the best compounds to late-stage development."

— Dr. James McKerrow, UCSF

"In one minute we can view multiple bioassay results that would have literally taken days. We can see everything in one place and we simply couldn't do that before investing in CDD."

— Karen Tenney, Crews Lab Manager, UC Santa Cruz

"I am very happy with the database. This is the primary information source for me to design compounds."

— Director of Chemistry, biotech company in Colorado

"An absolutely must have."

— Farhad Parhami, PhD, Associate Professor of Medicine, UCLA

"By far better than anything I’ve seen."

— Joel Freundlich, PhD, Princeton

"It's a great tool for mining and sharing data with collaborators. I've used a couple of other programs, but they don't put everything together so intuitively."

— Mary Lynn Baniecki, PhD, Clardy Laboratory, Harvard Medical School

"Just wanted to thank you for your help and all your effort getting our database up and running. I finally got everything uploaded and mapped, and it works fantastically!!! It's exactly what I wanted. You really hit a home run with this. The new version of the search software is also great, including the decreased cutoff value for % similarity. I'll keep you updated how the searches go."

— Ben Gold, PhD, Cornell Medical School

"Your application is remarkably impressive - there is no other word to describe it (and I've seen lots of other applications). Just the performance is mind-boggling!"

— Yannick Pouliot, PhD, MBA, Bioresearch Informationist, major research university in the SF Bay Area

"[CDD] provides a simple way to share screening data with collaborators."

—

S. Arastu-Kapur et al. "Identification of proteases that regulate erythrocyte rupture by the malaria parasite Plasmodium falciparum" Nature Chem. Biology, 4(3), 203-213, March 2008.

"Your networks, data sets and models more optimally utilize finite translational R&D resources… this is exactly what is needed today to more rapidly develop new treatments for neglected diseases."

— Gary K. Schoolnik, MD, Stanford University, School of Medicine

"Thanks for your help and to the engineers for the updates – the EC50 calculations are going to save me hours."

— Joe Planer, PhD, University of Washington, School of Medicine

"I was very impressed by the system's simplicity, responsiveness and functionality. It certainly looks better than anything I've seen so far."

— Wayne Best, PhD

"The CDD Database is an extremely elegant platform. I highly recommend it for anyone generating drug discovery data."

— Bryan Roth, MD, PhD, University of North Carolina